Cargando…
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708638/ https://www.ncbi.nlm.nih.gov/pubmed/36446771 http://dx.doi.org/10.1038/s41408-022-00758-7 |
| _version_ | 1784840980359282688 |
|---|---|
| author | Ramasamy, Karthik Iqbal, Gulnaz Brouwer, Richard Stalker, Victoria Akhtar, Salma Varghese, Sherin Lindsay, Jindriska Schey, Stephen Drayson, Mark Dunn, Janet |
| author_facet | Ramasamy, Karthik Iqbal, Gulnaz Brouwer, Richard Stalker, Victoria Akhtar, Salma Varghese, Sherin Lindsay, Jindriska Schey, Stephen Drayson, Mark Dunn, Janet |
| author_sort | Ramasamy, Karthik |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9708638 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97086382022-12-01 Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial Ramasamy, Karthik Iqbal, Gulnaz Brouwer, Richard Stalker, Victoria Akhtar, Salma Varghese, Sherin Lindsay, Jindriska Schey, Stephen Drayson, Mark Dunn, Janet Blood Cancer J Correspondence Nature Publishing Group UK 2022-11-29 /pmc/articles/PMC9708638/ /pubmed/36446771 http://dx.doi.org/10.1038/s41408-022-00758-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Ramasamy, Karthik Iqbal, Gulnaz Brouwer, Richard Stalker, Victoria Akhtar, Salma Varghese, Sherin Lindsay, Jindriska Schey, Stephen Drayson, Mark Dunn, Janet Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial |
| title | Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial |
| title_full | Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial |
| title_fullStr | Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial |
| title_full_unstemmed | Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial |
| title_short | Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial |
| title_sort | bortezomib, bendamustine and dexamethasone vs thalidomide, bendamustine and dexamethasone in myeloma patients presenting with renal failure (optimal): a randomised, multi-centre phase ii trial |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708638/ https://www.ncbi.nlm.nih.gov/pubmed/36446771 http://dx.doi.org/10.1038/s41408-022-00758-7 |
| work_keys_str_mv | AT ramasamykarthik bortezomibbendamustineanddexamethasonevsthalidomidebendamustineanddexamethasoneinmyelomapatientspresentingwithrenalfailureoptimalarandomisedmulticentrephaseiitrial AT iqbalgulnaz bortezomibbendamustineanddexamethasonevsthalidomidebendamustineanddexamethasoneinmyelomapatientspresentingwithrenalfailureoptimalarandomisedmulticentrephaseiitrial AT brouwerrichard bortezomibbendamustineanddexamethasonevsthalidomidebendamustineanddexamethasoneinmyelomapatientspresentingwithrenalfailureoptimalarandomisedmulticentrephaseiitrial AT stalkervictoria bortezomibbendamustineanddexamethasonevsthalidomidebendamustineanddexamethasoneinmyelomapatientspresentingwithrenalfailureoptimalarandomisedmulticentrephaseiitrial AT akhtarsalma bortezomibbendamustineanddexamethasonevsthalidomidebendamustineanddexamethasoneinmyelomapatientspresentingwithrenalfailureoptimalarandomisedmulticentrephaseiitrial AT varghesesherin bortezomibbendamustineanddexamethasonevsthalidomidebendamustineanddexamethasoneinmyelomapatientspresentingwithrenalfailureoptimalarandomisedmulticentrephaseiitrial AT lindsayjindriska bortezomibbendamustineanddexamethasonevsthalidomidebendamustineanddexamethasoneinmyelomapatientspresentingwithrenalfailureoptimalarandomisedmulticentrephaseiitrial AT scheystephen bortezomibbendamustineanddexamethasonevsthalidomidebendamustineanddexamethasoneinmyelomapatientspresentingwithrenalfailureoptimalarandomisedmulticentrephaseiitrial AT draysonmark bortezomibbendamustineanddexamethasonevsthalidomidebendamustineanddexamethasoneinmyelomapatientspresentingwithrenalfailureoptimalarandomisedmulticentrephaseiitrial AT dunnjanet bortezomibbendamustineanddexamethasonevsthalidomidebendamustineanddexamethasoneinmyelomapatientspresentingwithrenalfailureoptimalarandomisedmulticentrephaseiitrial |